Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone.
Tosi
Patrizia
P
Zamagni
Elena
E
Cangini
Delia
D
Tacchetti
Paola
P
Di Raimondo
Francesco
F
Catalano
Lucio
L
D'Arco
Alfonso
A
Ronconi
Sonia
S
Cellini
Claudia
C
Offidani
Massimo
M
Perrone
Giulia
G
Ceccolini
Michela
M
Brioli
Annamaria
A
Tura
Sante
S
Baccarani
Michele
M
Cavo
Michele
M
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects*; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000009:adverse effects*; D003907:Dexamethasone / Q000008:administration & dosage / Q000009:adverse effects; D004164:Diphosphonates / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000009:adverse effects*; D007571:Jaw Diseases / Q000139:chemically induced* / Q000209:etiology; D008297:Male; D009101:Multiple Myeloma / Q000150:complications* / Q000188:drug therapy; D010020:Osteonecrosis / Q000139:chemically induced* / Q000209:etiology; D012189:Retrospective Studies; D013792:Thalidomide / Q000008:administration & dosage / Q000009:adverse effects; D000077211:Zoledronic Acid
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D013792:Thalidomide; D000077211:Zoledronic Acid; D003907:Dexamethasone